Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors

S. Segaert1 and E. Van Cutsem2,*

1 Department of Dermatology, University Hospital, Katholieke Universiteit Leuven 2 Digestive Oncology Unit, University Hospital Gasthuisberg, Leuven, Belgium

* Correspondence to: Prof. Dr E. Van Cutsem, Digestive Oncology Unit, University Hospital Gasthuisberg, Herestraat 49, 3000 Leuven, Belgium. Tel: +32-16-344-218; Fax: +32-16-344-419; Email: eric.vancutsem{at}uz.kuleuven.ac.be


    Abstract
 Top
 Abstract
 Introduction
 Clinical findings
 Pathophysiology
 Management
 Conclusion
 References
 
The last few years, new therapies targeting the epidermal growth factor receptor (EGFR) have shown their efficacy in the treatment of several types of cancer. Monoclonal antibodies against the EGFR (e.g. cetuximab, panitumumab) or EGFR tyrosine kinase inhibitors (e.g. gefitinib, erlotinib) are generally well tolerated and do not have the severe systemic side-effects usually seen with cytotoxic drugs. A considerable number of patients treated with these EGFR inhibitors, however, develop dermatological side-effects, most frequently an acneiform eruption but also xerosis, eczema, fissures, telangiectasia, hyperpigmentation, hair changes and paronychia with pyogenic granuloma. These skin effects appear to be mechanism-based linked to the inhibition of EGFR action but the exact pathophysiology remains elusive. Left untreated these dermatological side-effects could represent a threat to patient compliance. Therefore effective management is mandatory. Mild cases of acneiform eruption respond well to topical anti-inflammatory acne therapy, whereas tetracyclines are needed to treat moderate to severe cases. This review outlines the broad spectrum of cutaneous side-effects of EGFR inhibitors, discusses possible underlying mechanisms and provides practical guidelines for the management based on literature data and on personal experience.

Key words: acneiform eruption, cetuximab, epidermal growth factor receptor, erlotinib, gefitinib


    Introduction
 Top
 Abstract
 Introduction
 Clinical findings
 Pathophysiology
 Management
 Conclusion
 References
 
Aberrant signalling through the epidermal growth factor receptor (EGFR) is associated with neoplastic cell proliferation, migration, stromal invasion, resistance to apoptosis and angiogenesis [1Go]. The high frequency of abnormalities in EGFR signalling in human carcinomas and preclinical studies showing that inhibition of EGFR can impair tumour growth, have made EGFR an attractive target for the development of cancer therapeutics [1Go]. Among the classes of agents targeting EGFR in clinical development are monoclonal antibodies against the extracellular ligand-binding domain of the receptor and small molecules that inhibit activation of the receptor tyrosine kinase [1Go]. Several of these molecules are under development in colorectal cancer (CRC) [2Go–7Go].

The chimeric antibody cetuximab has been investigated alone and in combination with irinotecan in patients with refractory metastatic colorectal cancer and has shown a consistent activity in EGFR-expressing chemotherapy-refractory CRC [2Go]. In the pivotal BOND study, the combination of cetuximab plus irinotecan led to a response rate of 23% in patients with irinotecan refractory EGFR-positive metastatic CRC and to a tumour stabilisation in 33% of patients. The response rate after cetuximab alone in this trial was 11% [2Go]. In this and other studies, no correlation was found between the strength of the EGFR expression as determined by immune-histochemistry and response rate [2Go, 8Go]. Therefore more tools are needed to define tumours in which EGFR inhibitors are really active.

Panitumumab (ABX-EGF) is a fully human monoclonal antibody that inhibits the EGFR. As monotherapy, a response rate of 11% has been found in chemorefractory CRC [4Go]. The humanised monoclonal antibody matuzumab (EMD72000 is in early phase 2 development in different tumour types [5Go]. The EGFR tyrosine kinase inhibitors gefitinib, erlotinib and EKB-569 have been studied less extensively in CRC, but seem to be less active in CRC [6Go, 7Go].

EGFR inhibitors are generally well tolerated and do not have the severe systemic side-effects usually seen with cytotoxic drugs. However, they often cause signs of skin toxicity, most often an acneiform eruption [2Go–10Go]. A correlation has been suggested between the acneiform eruption and EGFR inhibitor antitumour activity [2Go, 3Go, 10Go]. Prospective studies including skin and tumour biopsies are, however, needed to clarify and explain this possible relationship.


    Clinical findings
 Top
 Abstract
 Introduction
 Clinical findings
 Pathophysiology
 Management
 Conclusion
 References
 
Acneiform eruption
The most frequently reported side-effect of EGFR inhibitors (both monoclonal antibodies and tyrosine kinase inhibitors) is an acneiform eruption [2Go–17Go]. The rash seems to be dose-dependent [4Go, 11Go, 12Go, 14Go, 17Go] and is seen in more than 50% up to 100% of patients (Table 1). Further studies are ongoing to understand this dose relationship better.


View this table:
[in this window]
[in a new window]
 
Table 1. Incidence of acneiform eruption during therapy with EGFR inhibitors

 
In clinical studies, the acneiform eruption caused by EGFR inhibitors is usually classified according to the National Cancer Institute Common Toxicity Criteria version 2.0 (NCI CTC v2.0) [2Go, 3Go, 5Go, 12Go, 14Go, 15Go, 18Go] (Table 2) or the more recent National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0 (NCI CTCAE v3.0) [19Go]. Only a small portion (most often less than 5% up to 18%) of the patients experience a grade 3 reaction (Table 1). However, these criteria exhibit some shortcomings that do not always allow accurate classification of the skin rash [9Go]. In this respect, version 2 attaches great value to body surface involvement which is, however, very difficult to score in a follicular eruption. Version 3 introduces a special category on acneiform eruption that is at the same time very pragmatic and highly susceptible to interpretation (Table 2).


View this table:
[in this window]
[in a new window]
 
Table 2. Simplified classification of acneiform eruption caused by EGFR inhibitors [19Go]

 
The eruption is more or less confined to the seborrheic areas (rich in sebaceous glands): the face, the neck and retroauricular area, the shoulders, the upper trunk (V-shaped) (Figure 1A, ) and the scalp. Sometimes the lower parts of the back, the abdomen, the buttocks and even the arms and legs can be involved as well, whereas the palms and soles are spared [20Go–27Go]. The eruption is similar in patients receiving tyrosine kinase inhibitors or monoclonal antibodies but tends to be more severe and widespread with the latter [26Go].



View larger version (96K):
[in this window]
[in a new window]
 
Figure 1. Acneiform eruption. (A) papular lesions on the chest, (B) V-shaped papulopustular eruption on the back, (C) close up of follicular pustules, (D) confluent pustules on the nose.

 
The skin lesions consist of sometimes itchy erythematous follicular papules (Figure 1A) that may evolve into pustules [20Go–27Go] (Figure 1B, ). The pustules may confluate to lakes of pus that dry out with the formation of yellow crusts (Figure 1D) [26Go]. Sometimes the facial lesions consist of diffuse erythema with follicular papulopustules and telangiectasia resembling rosacea. In other cases a seborrheic dermatitis-like picture is seen on the face [25Go] when the pustules leave an erythema covered with small greasy squames. Rarely the rash presents with an oedematous, warm erythema of the face mimicking an erysipelas. Very rarely the cutaneous inflammation is so pronounced that skin necrosis with black eschar formation and ulceration is seen. The follicular skin lesions are not preceded by visible comedones (blackheads or whiteheads) and can therefore not be considered as a true acne [23Go, 24Go, 27Go, 28Go]. In contrast to acneiform eruptions caused by other drugs [28Go], EGFR inhibitor-induced skin lesions may be accompanied by pruritus.

The acneiform eruption arises a few days after treatment with the EGFR inhibitor, to reach a maximum after 2 [9Go] to 3 weeks [2Go] following commencement of the therapy. More rarely (11%) the rash occurs in a delayed fashion after the first 3 weeks of treatment (with cetuximab) [2Go]. Some spontaneous improvement can be seen even when treatment is continued [9Go]. However, a flare-up of the rash can occur following each infusion of further treatment [23Go]. The eruption disappears in a few weeks time when treatment is discontinued leaving sometimes residual hyperpigmentation and xerosis [21Go]. No relationship has yet been observed between the appearance or severity of the rash and a history of oily skin, acne [20Go] or rosacea.

Microscopic evaluation of the skin lesions shows a picture of a neutrophilic folliculitis and perifolliculitis [20Go, 21Go, 23Go, 26Go]. An early infiltration with T-lymphocytes is followed by a hyperkeratotic, ectatic appearance of the follicular infundibula and a florid, neutrophilic suppurative infiltrate [20Go]. Intra-epidermal acantholysis is sometimes present but the significance of this finding is unknown [20Go]. In contrast to true acne, no clear formation of comedones is seen [28Go], although the absence of early biopsy specimens cannot exclude the formation of a microcomedo as the trigger of inflammation. The pustules are notably sterile with negative cultures or stainings for bacteria, fungi, yeasts (including Malassezia furfur) or Demodex mites [23Go, 24Go] but no quantitative or longitudinal microbiological investigations have been carried out yet. The (pre-existing?) presence of Propionibacterium acnes or Malassezia furfur could only be demonstrated in a few exceptional cases [20Go, 21Go, 24Go].

Xerosis and related changes
Patients receiving EGFR inhibitors can gradually develop a dry skin over weeks resembling the xerosis in atopic eczema [21Go, 25Go, 27Go]. Patient's old age, previous therapy with cytotoxics and history of atopic eczema will accentuate the cutaneous dryness, which manifests with dry, scaly, itchy skin especially of the limbs and of skin areas that were affected by acneiform eruption [21Go]. The xerosis may develop into chronic asteatotic eczema. When secondary infection of the xerotic skin with Staphylococcus aureus occurs, a flare-up of acute oozing dermatitis and sometimes yellow crusting may be seen. Rarely the compromised epidermal barrier in these patients is the portal of entry for secondary infection with herpes simplex virus, manifesting with a monomorphous picture with numerous tiny vesicles. The fingertops and toes may develop a dry pulpitis with dry scaly eczema. Painful fissures may arise on the fingers and toes, mainly at the tops, in the nail folds and over the interphalangeal joints [20Go, 27Go] (Figure 2). Along with the xerosis, increased skin fragility and easy bruising are observed in patients receiving EGFR inhibitors [21Go]. Sometimes involvement of the mucosae can be seen with vaginal dryness [27Go] or aphtous ulcers of the oral or nasal mucosa [20Go, 25Go].



View larger version (107K):
[in this window]
[in a new window]
 
Figure 2. Xerosis, dry eczema and fissure over the interphalangeal joint of the finger.

 
Nail changes
Nail changes are seen in 10%–15% of patients and are a late event (starting usually not earlier than 4–8 weeks) during the treatment course [25Go]. Paronychia manifesting with inflammation of the nail fold (mainly of the great toe; other toes and fingers may be involved as well) is usually the first sign [20Go]. This paronychia can be very painful and mimics an ingrown toenail in the severe cases where pyogenic granuloma of the nail fold develops [25Go, 29Go–32Go] (Figure 3). Secondary infection with Staphylococcus aureus is not uncommon [30Go, 32Go] and painful fissures sometimes arise in the nail folds [27Go]. The nails tend to grow more slowly; they are more brittle and sometimes crack [27Go].



View larger version (108K):
[in this window]
[in a new window]
 
Figure 3. Paronychia and pyogenic granuloma of the nail fold of the big toe.

 
Hair changes
During prolonged treatment with EGFR inhibitors, changes of the hairs can be noticed. Very characteristic are the long, curly, rigid eyelashes, also named trichomegaly [33Go, 34Go] (Figure 4). The eyebrows become thicker and more rigid as well [34Go] whereas the scalp hairs grow more slowly and adopt a finer, more brittle and curly aspect [21Go]. In addition less shavings of the beard are required. Mild hair loss can be seen on the scalp, arms or legs, whereas hypertrichosis with small vellus hairs may develop on the face and the female lip.



View larger version (114K):
[in this window]
[in a new window]
 
Figure 4. Trichomegaly (long curly eyelashes).

 
Telangiectasia
Early during the development of acneiform eruption or with subsequent flares of the rash, scattered telangiectasia (Figure 5) may appear on the face, on and behind the ears, on the chest, back and limbs, usually in the vicinity of a follicular pustule. Unlike other telangiectasia, the lesions tend to fade over months usually leaving some hyperpigmentation.



View larger version (114K):
[in this window]
[in a new window]
 
Figure 5. Telangiectasia.

 
Hyperpigmentation
Post-inflammatory hyperpigmentation [32Go] is typically seen following acneiform eruption (Figure 6) or other causes of skin inflammation such as eczema or an inflamed sebaceous cyst. Sun exposure aggravates the hyperpigmentation.



View larger version (164K):
[in this window]
[in a new window]
 
Figure 6. Hyperpigmentation following acneiform eruption with also some new erythematous lesions.

 

    Pathophysiology
 Top
 Abstract
 Introduction
 Clinical findings
 Pathophysiology
 Management
 Conclusion
 References
 
Several factors plead in favour of a mechanism-based side-effect that is directly linked to specific inhibition of the EGFR. First, similar cutaneous effects develop regardless of the mechanism of action of the EGFR inhibitor as a monoclonal antibody (cetuximab, panitumumab, matuzumab) [2Go–5Go, 17Go] or as an EGFR-specific tyrosine kinase inhibitor (gefitinib, erlotinib) [12Go, 14Go, 15Go, 18Go]. Moreover, acneiform eruption or nail changes are not seen with inhibitors of other EGFR family members such as trastuzumab, a monoclonal antibody against HER2 receptor [35Go]. Secondly, the cutaneous effects appear to be dose-dependent as shown for gefitinib [12Go, 14Go] and panitumumab (ABX-EGF) [4Go, 17Go]. Thirdly, there is growing evidence for a possible correlation between tumour response and the presence or extent of skin rash as demonstrated with cetuximab [2Go, 3Go, 10Go, 36Go], panitumumab [17Go], erlotinib [15Go, 18Go, 37Go] and gefitinib [8Go, 38Go]. Hence there is an ongoing discussion about the use of skin side-effects as a surrogate marker for pharmacodynamic effects of EGFR inhibitors [39Go] and about (‘dose-to-rash’) strategies to titrate the EGFR inhibitor dose in individual patients to a level that causes detectable skin rash. A randomised study is ongoing in which patients with no rash or rash grade 1 are randomised between an increasing dose of cetuximab plus irinotecan or the recommended dose of cetuximab plus irinotecan (EVEREST study). In this study, skin and tumour biopsies are taken before and during treatment to understand better the mechanism of this EGFR inhibitor-induced rash. Very recently, a polymorphism in the intron 1 of the EGFR gene that affects transcription efficiency of the gene, was found to correlate with both tumour response and skin toxicity [40Go]. Fourthly, EGFR-null skin of genetically engineered mice is very dry, flaky and covered with a thin epidermis [41Go]. Moreover, extensive hair follicle defects result not only in thin and brittle hair but also in a mixed inflammatory infiltration at the hair follicle with rupture of the follicular epithelium [42Go], findings that are strikingly similar to the skin changes induced by EGFR inhibitors.

In the spectrum of drug-induced skin changes, the combination of the itchy acneiform eruption, xerosis, paronychia, hair changes and telangiectasia is entirely unique. Classical inducers of acneiform eruption are corticosteroids, vitamin B and antiepileptics, but this rash usually does not itch and is not accompanied by the other skin findings elicited by EGFR inhibitors [28Go]. Oral retinoids may induce xerosis and paronychia but not acneiform changes [43Go]. The only common finding in the kaleidoscope of dermatologic effects induced by EGFR inhibitors is that they occur in sites where EGFR is known to be expressed, namely the basal epidermal cells, sebaceous glands, hair follicle outer root sheath and hair shaft and the capillary system [44Go].

The mechanism by which inhibition of EGFR leads to acneiform eruption and the other dermatologic symptoms is largely unknown. EGFR activation serves essential functions in the skin such as the promotion of keratinocyte proliferation, survival and motility and the regulation of differentiation and keratinisation [45Go]. Hence EGFR occupies a central role in carcinogenesis, psoriasis and wound healing [45Go]. Wound healing problems are, however, not seen with EGFR inhibitors. Numerous pharmacodynamic studies have confirmed molecular effects in the skin of patients treated with different EGFR inhibitors. Not unexpectedly, a dramatic decrease of the phosphorylation status of the EGFR in the epidermis and in the percentage of activated MAPK-positive epidermal cells was noticed in gefitinib-treated patients [12Go] together with thinning of the corneal layers, decreased labelling of cells with the proliferation marker Ki67 and increased numbers of cells that are immunohistochemically positive for the cyclin-dependent kinase inhibitor p27, a marker for growth arrest [46Go]. Epidermal p27 upregulation was also seen in cetuximab-treated patients [20Go] as well as decreased thickness of stratum corneum and decreased Ki67 labelling following erlotinib therapy [16Go]. The keratinocyte growth arrest and thinning of the corneal layers is in line with EGFR's role in maintaining keratinocyte proliferation [45Go] and in promoting late terminal differentiation [47Go] but is hard to explain the acneiform aspect of the eruption (a follicular papulopustular eruption mostly confined to the seborrheic areas) observed in the majority of patients receiving EGFR inhibitors. The expression of EGFR in the pilosebaceous unit, both in follicular keratinocytes and in sebocytes [44Go], is likely to play an, as yet, unidentified but major role in the follicular localisation of the eruption in regions rich in sebaceous glands. Similar folliculitis changes in the skin of EGFR knockout mice confirm the importance of EGFR in the hair follicle (or pilosebaceous unit) [42Go].

The study of the pathophysiology of acne or acneiform eruptions is considerably hampered by the lack of reliable animal models [28Go]. In an in vitro acne model system, EGF was recently demonstrated to facilitate the development of acne by causing disorganisation of infundibular keratinocytes enhancing the entry of inflammatory sebum into the dermis [48Go]. These results sharply contrast with the acneiform eruption in patients on EGFR inhibitors. This discrepancy may be explained by the limitations of the in vitro model or by the fact that both EGFR overstimulation and inhibition lead to disorganisation of the pilosebaceous unit leading to follicular inflammation. In addition, it should be stressed that no blackheads or whiteheads precede the follicular papules or pustules of an acneiform eruption, unlike acne, which typically starts with the formation of comedones by follicular hypercornification due to seborrhoea [28Go].

Until now, most of the considerations about the mechanisms behind EGFR inhibitor-induced acneiform eruption imply effects on (follicular) keratinocyte proliferation and differentiation that cause secondary inflammation. However, EGFR targeted therapies may affect the immune system more directly as well, by unblocking cutaneous chemokine production resulting in leukocyte chemotaxis and infiltration in the skin based on a recent study attributing a role to cutaneous EGFR in the suppression of chemokine production [49Go].

The EGFR inhibitor-induced xerosis can be explained more easily by the established role of EGFR in the maintenance of the integrity of the epidermal permeability barrier [50Go], whereas the skin fragility and epidermal thinning refer to the involvement of EGFR in keratinocyte proliferation, differentiation and survival [45Go]. Moreover dryness and fragility of the skin can be reproduced in EGFR knockout mice [41Go].

The hair changes reflect the role of EGFR and its ligands in hair follicle biology and hair cycling. Similar hair changes can be seen in transgenic mice or spontaneous mutants affecting EGFR, its ligands or its partner receptors [42Go, 51Go–53Go], including long and curly whiskers corresponding to the trichomegaly in patients on EGFR inhibitors [33Go, 34Go].

Paronychia and pyogenic granuloma of the nail fold resemble the side-effects of systemic retinoids [43Go]. Retinoids are also well known to cause xerosis but no acneiform eruption, telangiectasia or hyperpigmentation [43Go]. This partly overlapping side-effect profile may be due to the downregulating effects of retinoids on the EGFR system [54Go] or alternatively to the similar effects of retinoids and EGFR inhibitors on epidermal proliferation and differentiation [43Go, 45Go]. Xerosis and desquamation of nail fold and nail bed epidermis may cause epidermal squames to be stuck between the nail plate and the surrounding epidermis inducing chronic irritation and inflammation [55Go]. The development of pyogenic granuloma may reflect effects on angiogenic factors such as vascular endothelial growth factor (VEGF) that are overexpressed in these lesions [56Go]. The effects of retinoids on VEGF expression in vitro are known to depend on culture conditions displaying inhibition as well as stimulation [57Go]. EGFR inhibitors have been demonstrated to inhibit VEGF expression and angiogenesis [58Go] but it is unknown whether these drugs could also induce VEGF in some tissues (skin) under certain circumstances. Moreover, the very peculiar development of telangiectasia could also be linked to disturbances in the production of angiogenic factors.


    Management
 Top
 Abstract
 Introduction
 Clinical findings
 Pathophysiology
 Management
 Conclusion
 References
 
Dermatological side-effects of EGFR inhibitors should be taken seriously since they can cause not only itch (acneiform eruption, xerosis, eczema) and pain (paronychia) but also cosmetic discomfort that may compromise compliance to therapy if left untreated. Therefore, it is important to inform patients about the possible side-effects, to provide preventive measures to minimise side-effects and to treat the skin symptoms when needed. Treatment is best individualised according to the type and the extent of the skin lesions. In this respect, choice of the right vehicle and frequent follow-ups to re-evaluate the skin lesions are important. A multidisciplinary approach with a dermatologist is advisable especially in the more severe cases. Publications on the management of skin toxicity of EGFR inhibitors are still very scarce [27Go, 59Go–61Go]. Here, we provide some practical guidelines based mainly on personal experience.

General measures
To ensure a maximal hydration of the skin, the use of bath oil or shower oil (instead of shower gel or soap) and of tepid water to wash should be encouraged. To prevent xerosis, an emollient cream (especially on the limbs) can be used. Sun exposure should be avoided and/or effective sun barrier preparations should be used to minimise the risk of hyperpigmentation.

Acneiform eruption
For mild grade 1 reactions, no treatment or treatment with topical anti-acne or anti-rosacea agents with anti-inflammatory properties can be started (e.g. metronidazole gel or cream, erythromycin or clindamycin gel or lotion, benzoylperoxide gel or cream on the face or salicylic acid in alcoholic lotion on chest/back). One should bear in mind that this topical treatment has drying properties and may aggravate xerosis. When the acneiform eruption is fading or becoming scaly, one should switch topical treatment to cream bases instead of alcoholic lotions or gels.

In patients treated with erlotinib, no effect was seen with topical retinoids, vitamin D analogues or steroids [9Go]. Except in the presence of eczema (see below), the use of topical or systemic steroids should be avoided since they are well known to induce or aggravate acne, acneiform eruption, rosacea or telangiectasia [28Go]. Moreover systemic steroids may interfere with the antibody-dependent cytotoxic action of EGFR antibodies. Although anticomedonal topicals such as retinoids (tretinoin) or {alpha}-hydroxyacids have been advocated in some reports [21Go, 61Go], we would not recommend them because of the lack of comedones [27Go] and the possible aggravation of xerosis and eczema [21Go].

For grade 2 reactions, topical treatment as for grade 1 can be used together with topical menthol cream or an oral antihistamine (cetirizine, loratadine, hydroxyzine) when itch is present and an oral tetracycline (minocycline 100 mg/day, lymecycline 300 mg/day or doxycycline 100 mg/day) [21Go, 23Go]. Thanks to their anti-inflammatory properties, tetracyclines exert marked anti-acne effects, when given in a course of at least 3 months [28Go]. Oral isotretinoin is not recommended because of its overlapping side-effect profile (xerosis, paronychia) [43Go] and its unknown interaction with the antitumoural properties of EGFR inhibitors.

In the case of grade 3 reactions, delay of therapy with EGFR inhibitors should be taken into consideration. In addition to the aforementioned topicals, compresses with physiologic solution can be applied in the case of acute inflammation. Oral anti-histamines and oral tetracyclines at high (maximal anti-inflammatory) doses (minocycline 2x100 mg/day, lymecycline 2x300 mg/day or doxycycline 2x100 mg/day) complete the treatment. The dose can be tapered as soon as the acute inflammation has faded.

Grade 4 reactions, although extremely seldom, should be treated in specialised burn care units and EGFR inhibitors should be immediately stopped for good.

Xerosis
Apart from the general hydrating measures, the right vehicle choice to treat skin conditions is indispensable to alleviate skin dryness. In this respect alcoholic lotions or gels should be discontinued when the first signs of dryness appear and switched to oil in water creams instead (on face/chest/back). On the limbs greasy (water in oil) creams or even ointments can be used for moderate to severe xerosis. The right balance should, however, always be kept since occlusive ointments may facilitate the development of folliculitis lesions. When eczema is present, topical weak corticosteroids are recommended for a short term (1–2 weeks). When eczema becomes wet, a swab for bacterial (or viral culture) can be taken and treatment with topical (fusidic acid) or in severe cases systemic antibiotics (penicillinase-resistant pennicillins) can be added. In the rare case of herpes simplex virus superinfection, treatment with systemic antiviral drugs is necessary. Fissures can be treated with propyleneglycol 50% solution under plastic occlusion, salicylic acid 10% ointment, a hydrocolloid dressing, flurandrenolone tape or liquid cyanoacrylate glue [27Go].

Paronychia
As a preventive measure, it is important to avoid friction and pressure on the nail fold by wearing shoes that are not too tight. The paronychia caused by EGFR blockers are not infective in nature but render the nail folds very sensitive to infection [30Go, 32Go]. Topical antiseptics or antibiotics (soaks and/or creams) should, therefore, be used on a regular basis. In our hands, a drying paste containing an antiseptic (chlorhexidine), an anti-yeast (nystatin) and in severe cases a topical corticosteroid [29Go, 31Go] has proved helpful in the treatment of paronychia. In case of secondary bacterial infection, oral antibiotics can be administered according to the antibiogram. Although the nail fold inflammation caused by EGFR inhibitors mimics the clinical picture of an ingrown nail, partial nail bed excision has no effect. Total nail extraction with destruction of nail matrix may help but then the nail is permanently lost (own experience). Silver nitrate application on a weekly basis will improve pyogenic granuloma.

Telangiectasia
Telangiectasia caused by treatment with EGFR inhibitors, unlike spontaneous telangiectasia, will gradually disappear over months. In selected cases electrocoagulation or pulsed dye laser therapy can be applied to accelerate disappearance.

Hyperpigmentation
Since the excessive pigmentation appears to be mostly postinflammatory in nature, adequate prevention and treatment of acneiform eruption and eczema is important. Another preventive measure is to avoid the unfavourable effect of the sun, by minimising sun exposure and encouraging the use of sun blocking creams. Bleaching creams are not very helpful; the hyperpigmentation will fade spontaneously with time (months).


    Conclusion
 Top
 Abstract
 Introduction
 Clinical findings
 Pathophysiology
 Management
 Conclusion
 References
 
Cutaneous effects of EGFR inhibitors represent a totally unique new group of class-specific side-effects consisting essentially of an itchy acneiform papulopustular eruption, telangiectasia and xerosis. During longer treatment nail fold inflammation, hair changes and hyperpigmentation may also arise. These side-effects compare well in their tolerance to those seen with cytotoxic drugs. The underlying mechanisms are poorly understood but are most likely linked to inhibition of EGFR in the skin. As there is growing evidence of a relationship between treatment efficacy and rash, the rash may serve as a surrogate marker for tumour response. Although the numbers treated are small, in our experience the acneiform eruption responds well to topical anti-acne therapy and tetracycline antibiotics, whereas emollients are recommended for the skin xerosis. Future clinical research is required to meet the need for a more accurate classification (in order to better define the relation between skin effects and tumour response) and for more evidence-based treatment of skin toxicity.

Received for publication February 3, 2005. Revision received May 3, 2005. Accepted for publication May 3, 2005.


    References
 Top
 Abstract
 Introduction
 Clinical findings
 Pathophysiology
 Management
 Conclusion
 References
 
1. Castillo L, Etienne-Grimaldi MC, Fischel JL et al. Pharmacological background of EGFR targeting. Ann Oncol 2004; 15: 1007–1012.[Abstract/Free Full Text]

2. Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337–345.[Abstract/Free Full Text]

3. Saltz L, Meropol NJ, Loehrer PJ et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22: 1201–1208.[Abstract/Free Full Text]

4. Foon KA, Yang X-D, Weiner LM et al. Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. Int J Radiation Oncology Biol Phys 2004; 58: 984–990.[CrossRef][ISI][Medline]

5. Vanhoefer U, Twes M, Rojo F et al. Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor. J Clin Oncol 2004; 22: 175–184.[Abstract/Free Full Text]

6. Seymour L, Goss G, Stewart D. A translational research study of ZD1839 at a dose of 750 mg in patients with pretreated advanced or metastatic colorectal cancer: NCIC CTG IND.122. Ann Oncol 2002; 13: S5 (Abstr 264PD).

7. Oza AM, Townsley CA, Siu LL et al. Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 2003; 22: 196 (Abstr 785).

8. Kris MG, Natale RB, Herbst RS et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer. JAMA 2003; 290: 2149–2158.[Abstract/Free Full Text]

9. Hidalgo M, Siu LL, Nemunaitis J et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2001; 19: 3267–3279.[Abstract/Free Full Text]

10. Van Cutsem E, Mayer R, Gold P et al. Correlation of acne rash and tumor response with cetuximab monotherapy in patients with colorectal cancer refractory to both irinotecan and oxaliplatin. Eur J Cancer 2004; 2 (Suppl): 85–86 (Abstr 279).

11. Baselga J, Pfister D, Cooper MR et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 2000; 18: 904–914.[Abstract/Free Full Text]

12. Baselga J, Rischin D, Ranson M et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 2002; 20: 4292–4302.[Abstract/Free Full Text]

13. Malik SN, Siu LL, Rowinsky EK et al. Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients. Clin Cancer Res 2003; 9: 2478–2486.[Abstract/Free Full Text]

14. Ranson M, Hammond LA, Ferry D et al. ZD1839, a selective oral epidermal growth factor receptor—tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol 2002; 20: 2240–2250.[Abstract/Free Full Text]

15. Soulieres D, Senzer NN, Vokes EE et al. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 2004; 22: 77–85.[Abstract/Free Full Text]

16. Tan AR, Yang X, Hewitt SM et al. Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor. J Clin Oncol 2004; 22: 3080–3090.[Abstract/Free Full Text]

17. Rowinsky EK, Schwartz GH, Jared A et al. Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J Clin Oncol 2004; 22: 3003–3015.[Abstract/Free Full Text]

18. Perez-Soler R, Chachoua A, Hammond LA et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 2004; 22: 3238–3247.[Abstract/Free Full Text]

19. National Cancer Institute. Common Terminology Criteria for Adverse Events v3.0. http://www.ctep.cancer.gov/reporting/ctc.html.

20. Busam KJ, Capodieci P, Motzer R et al. Cutaneous side-effects in patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol 2001; 144: 1169–1176.[CrossRef][ISI][Medline]

21. Kimyai-Asadi A, Jih MH. Follicular toxic effects of chimeric anti-epidermal growth factor receptor antibody cetuximab used to treat human solid tumors. Arch Dermatol 2002; 138: 129–131.[Free Full Text]

22. Van Doorn R, Kirtschig G, Scheffer E et al. Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor. Br J Dermatol 2002; 147: 598–601.[CrossRef][ISI][Medline]

23. Walon L, Gilbeau C, Lachapelle J-M. Eruptions acnéiformes induites par le cétuximab. Ann Dermatol Venereol 2003; 130: 443–446.[ISI][Medline]

24. Fernandez-Galar M, Espana A, Lopez-Picazo JM. Acneiform lesions secondary to ZD1839, an inhibitor of the epidermal growth factor receptor. Clin Exp Dermatol 2004; 29: 138–140.[CrossRef][ISI][Medline]

25. Lee MW, Seo CW, Kim SW et al. Cutaneous side effects in non-small cell lung cancer patients treated with Iressa (ZD1839), an inhibitor of epidermal growth factor. Acta Derm Venereol 2004; 84: 23–26.[ISI][Medline]

26. Jacot W, Bessis D, Jorda E et al. Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours. Br J Dermatol 2004; 151: 238–241.[CrossRef][ISI][Medline]

27. Shah NT, Kris MG, Pao W et al. Practical management of patients with non-small-cell lung cancer treated with gefitinib. J Clin Oncol 2005; 23: 165–174.[Abstract/Free Full Text]

28. Plewig G, Kligman AM. Acne and rosacea. 3rd edition. Berlin: Springer-Verlag 2000.

29. Boucher KW, Davidson K, Mirkhur B et al. Paronychia induced by cetuximab, an antiepidermal growth factor receptor antibody. J Am Acad Dermatol 2002; 45: 632–633.[CrossRef][ISI]

30. Dainichi T, Tanaka M, Tsuruta N et al. Development of multiple paronychia and periungual granulation in patients treated with gefitinib, an inhibitor of epidermal growth factor receptor. Dermatology 2003; 207: 324–325.[CrossRef][ISI][Medline]

31. Nakano J, Nakamura M. Paronychia induced by gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor. J Dermatol 2003; 30: 261–262.[CrossRef][ISI][Medline]

32. Chang GC, Yang T-Y, Chen K-C et al. Paronychia and skin hyperpigmentation induced by gefitinib in advanced non-small-cell lung cancer. J Clin Oncol 2004; 22: 4646–4648.[Free Full Text]

33. Dueland S, Sauer T, Lund-Johansen F et al. Epidermal growth factor receptor inhibition induces trichomegaly. Acta Oncol 2003; 42: 345–346.[CrossRef][ISI][Medline]

34. Pascual JC, Banuls J, Belinchon I et al. Trichomegaly following treatment with gefitinib (ZD1839). Br J Dermatol 2004; 151: 1111–1112.[CrossRef][ISI][Medline]

35. Vogel CL, Cobleigh MA, Tripathy D et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20: 719–726.[Abstract/Free Full Text]

36. Saltz L, Kies M, Abbruzzese JL et al. The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignancies. Proc Am Soc Clin Oncol 2003; 22: 204 (Abstr).

37. Perez-Soler R. Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome? Oncology 2003; 11 (Suppl 12): 23–28.

38. Mohamed MK, Ramalingam S, Lin Y et al. Skin rash and good performance status predict improved survival with gefitinib in patients with advanced non-small-cell lung cancer. Ann Oncol 2005; 16: 780–785.[Abstract/Free Full Text]

39. Baselga J. Skin as a surrogate tissue for pharmacodynamic end points: is it deep enough? Clin Cancer Res 2003; 9: 2389–2390.[Free Full Text]

40. Amador ML, Oppenheimer D, Perea S et al. An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors. Cancer Res 2004; 64: 9139–9143.[Abstract/Free Full Text]

41. Threadgill DW, Dlugosz AA, Hansen LA et al. Targeted disruption of mouse EGF receptor: effect of genetic background on mutant phenotype. Science 1995; 269: 230–234.[ISI][Medline]

42. Hansen LA, Alexander N, Hogan ME et al. Genetically null mice reveal a central role for epidermal growth factor receptor in the differentiation of the hair follicle and normal hair development. Am J Pathol 1997; 150: 1959–1975.[Abstract]

43. DiGiovanna. Systemic retinoid therapy. Dermatol Clin 2001; 19: 161–167.[CrossRef][ISI][Medline]

44. Green MR, Couchman JR. Differences in human skin between the epidermal growth factor receptor distribution detected by EGF binding and monoclonal antibody recognition. J Invest Dermatol 1985; 85: 239–245.[CrossRef][ISI][Medline]

45. Jost M, Karl C, Rodeck U. The EGF receptor—an essential regulator of multiple epidermal functions. Eur J Dermatol 2000; 10: 505–510.[ISI][Medline]

46. Albanell J, Rojo F, Averbuch S et al. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 2001; 20: 110–124.[CrossRef][ISI]

47. Wakita H, Takiga M. Activation of epidermal growth factor receptor promotes late terminal differentiation of cell-matrix interaction-disrupted keratinocytes. J Biol Chem 1999; 274: 37285–37291.[Abstract/Free Full Text]

48. Guy R, Kealey T. Modelling the infundibulum in acne. Dermatology 1998; 196: 32–37.[CrossRef][ISI][Medline]

49. Mascia F, Mariani V, Girolomoni G, Pastore S. Blockade of the EGF receptor induces a deranged chemokine expression in keratinocytes leading to enhanced skin inflammation. Am J Pathol 2003; 163: 303–312.[Abstract/Free Full Text]

50. Mimeault M, Bonenfant D, Batra SK. New advances on the functions of epidermal growth factor receptor and ceramides in skin cell differentiation. Skin Pharmacol Physiol 2004; 17: 153–166.[ISI][Medline]

51. Murillas R, Larcher F, Conti CJ et al. Expression of a dominant negative mutant of epidermal growth factor receptor in the epidermis of transgenic mice elicits striking alterations in hair follicle development and skin structure. EMBO J 1995; 14: 5216–5223.[Abstract]

52. Xie W, Wu X, Chow LT et al. Targeted expression of activated erbB-2 to the epidermis of transgenic mice elicits striking developmental abnormalities in the epidermis and hair follicles. Cell Growth Differ 1998; 9: 313–325.[Abstract]

53. Kiguchi K, Bol D, Carbajal S et al. Constitutive expression of erbB2 in epidermis of transgenic mice results in epidermal hyperproliferation and spontaneous skin tumor development. Oncogene 2000; 19: 4243–4254.[CrossRef][ISI][Medline]

54. Averbuch SD. Lung cancer prevention: retinoids and the epidermal growth factor receptor—a phoenix rising? Clin Cancer Res 2002; 8: 1–3.[Free Full Text]

55. Baran R. Etretinate and the nails (study of 130 cases): possible mechanisms of some side-effects. Clin Exp Dermatol 1986; 11: 148–152.[ISI][Medline]

56. Bragado R, Bello E, Requena L et al. Increased expression of vascular endothelial growth factor in pyogenic granulomas. Acta Derm Venereol 1999; 79: 422–425.[CrossRef][ISI][Medline]

57. Weninger W, Rendl M, Mildner M et al. Retinoids downregulate vascular endothelial growth factor/vascular permeability factor production by normal human keratinocytes. J Invest Dermatol 1998; 111: 907–911.[CrossRef][ISI][Medline]

58. Perrotte P, Matsumoto T, Inoue K et al. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res 1999; 5: 257–265.[Abstract/Free Full Text]

59. Purdom M. Management of acneiform rashes related to gefitinib therapy. Clin J Oncol Nurs 2004; 8: 316–317.[Medline]

60. Herbst RS, LoRusso PM, Purdom M, Ward D. Dermatological side effects associated with gefitinib therapy: clinical experience and management. Clin Lung Cancer 2003; 4: 366–369.[Medline]

61. Cortesi E, De Pasquale Ceratti A, D'Auria G et al. Management of cutaneous adverse effects during treatment with ZD1838 in advanced non-small cell lung cancer (NSCLC): surprising efficacy of early local treatment. J Clin Oncol 2004; 22 (Suppl): (Abstr 7100).





This Article
Abstract
Full Text (PDF)
All Versions of this Article:
16/9/1425    most recent
mdi279v1
E-letters: Submit a response
Alert me when this article is cited
Alert me when E-letters are posted
Alert me if a correction is posted
Services
Email this article to a friend
Similar articles in this journal
Similar articles in PubMed
Alert me to new issues of the journal
Add to My Personal Archive
Download to citation manager
Disclaimer
Request Permissions
Google Scholar
Articles by Segaert, S.
Articles by Van Cutsem, E.
PubMed
PubMed Citation
Articles by Segaert, S.
Articles by Van Cutsem, E.